Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD) from its SEC filings: 2025 revenue $0, free cash flow -$54.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $0 |
| Net income | -$57.6 million |
| Free cash flow | -$54.3 million |
| Diluted EPS | $-2.93 |
| Cash | $73.8 million |
| Share count, 1 year | +1% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-27. Education only, not financial advice.